Publications by authors named "Matthew Loza"

Claim this Profile
S
Safety, tolerability, and efficacy of the PD-1 agonist antibody JNJ-67484703 in adults with active rheumatoid arthritis: results of a multicenter, double-blind, placebo-controlled, randomized, multiple-dose phase Ib study.
Irving T C Ling, Stanley J Marciniak, Stephen H Clarke, Vani Lakshminarayanan, Matthew J Loza

Ther Adv Musculoskelet Dis· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamic, prognostic, and predictive biomarkers in severe and critical COVID-19 patients treated with sirukumab.
Kim Thys, Matthew J Loza, Linghua Lynn, Katleen Callewaert, Lisa Varma

Sci Rep· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study.
Peter C Taylor, Georg Schett, Tom Wj Huizinga, Qingmin Wang, Fowzia Ibrahim, Matthew J Loza

RMD Open· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Using an electronic diary and wristband accelerometer to detect exacerbations and activity levels in COPD: a feasibility study.
Lydia J Finney, Stefan Avey, Dexter Wiseman, Anthony Rowe, Matthew J Loza

ERJ Open Res· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serologic Biomarkers of Progression Toward Diagnosis of Rheumatoid Arthritis in Active Component Military Personnel.
Matthew J Loza, Sunil Nagpal, Suzanne Cole, Renee M Laird, Ashley Alcala

Arthritis Rheumatol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Collagen Turnover Biomarkers Associate with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase 3 Clinical Trial (DISCOVER-2).
Georg Schett, Matthew J Loza, Arumugam Palanichamy, Oliver FitzGerald, Christopher Ritchlin

Rheumatol Ther· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Publisher Correction to: Collagen Turnover Biomarkers Associate with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase 3 Clinical Trial (DISCOVER-2).
Georg Schett, Matthew J Loza, Arumugam Palanichamy, Oliver FitzGerald, Christopher Ritchlin

Rheumatol Ther· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Urinary metabotype of severe asthma evidences decreased carnitine metabolism independent of oral corticosteroid treatment in the U-BIOPRED study.
Stacey N Reinke, Shama Naz, Romanas Chaleckis, Hector Gallart-Ayala, Johan Kolmert, Matthew Loza

Eur Respir J· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and transcriptomic features of persistent exacerbation-prone severe asthma in U-BIOPRED cohort.
Uruj Hoda, Stelios Pavlidis, Aruna T Bansal, Kentaro Takahashi, Sile Hu, Matthew Loza

Clin Transl Med· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials.
Kristen Sweet, Qingxuan Song, Matthew J Loza, Iain B McInnes, Keying Ma

RMD Open· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Suppression of Serum Interferon-γ Levels as a Potential Measure of Response to Ustekinumab Treatment in Patients With Systemic Lupus Erythematosus.
Matteo Cesaroni, Loqmane Seridi, Matthew J Loza, Jessica Schreiter, Kristen Sweet

Arthritis Rheumatol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Instability of sputum molecular phenotypes in U-BIOPRED severe asthma.
Nazanin Z Kermani, Stelios Pavlidis, Jiaxing Xie, Kai Sun, Matthew Loza

Eur Respir J· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Type 2-low asthma phenotypes by integration of sputum transcriptomics and serum proteomics.
Nazanin Zounemat Kermani, Mansoor Saqi, Paul Agapow, Stelios Pavlidis, Chihhsi Kuo, Matthew Loza

Allergy· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The CSF-1-receptor inhibitor, JNJ-40346527 (PRV-6527), reduced inflammatory macrophage recruitment to the intestinal mucosa and suppressed murine T cell mediated colitis.
Carl L Manthey, Beverley A Moore, Yanqing Chen, Matthew J Loza, Xiang Yao

PLoS One· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cohort profile of a US military population for evaluating pre-disease and disease serological biomarkers in rheumatoid and reactive arthritis: Rationale, organization, design, and baseline characteristics.
Chad K Porter, Mark S Riddle, Renee M Laird, Matthew Loza, Suzanne Cole

Contemp Clin Trials Commun· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sirukumab and adalimumab reduce power Doppler ultrasound signal in patients with rheumatoid arthritis by 4 weeks in a phase III trial.
Kristen Sweet, Bidisha Dasgupta, Dick de Vries, Ian Gourley, Benjamin Hsu, Matthew J Loza

Ann Rheum Dis· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Responsiveness of Serum C-Reactive Protein, Interleukin-17A, and Interleukin-17F Levels to Ustekinumab in Psoriatic Arthritis: Lessons From Two Phase III, Multicenter, Double-Blind, Placebo-Controlled Trials.
Stefan Siebert, Kristen Sweet, Bidisha Dasgupta, Kim Campbell, Iain B McInnes, Matthew J Loza

Arthritis Rheumatol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Cryo-pulverization Protocol for Processing Mouse Paws to Evaluate Molecular Pathways of Tissue Inflammation in a Collagen Induced Arthritis Model.
Brian Jones, Shannon Hitchcock, Matthew Loza, Ravi Malaviya, Tatiana Ort

J Vis Exp· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contribution of airway eosinophils in airway wall remodeling in asthma: Role of MMP-10 and MET.
Chih-Hsi S Kuo, Stelios Pavlidis, Jie Zhu, Matthew Loza, Fred Baribaud

Allergy· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined Blockade of TNF-α and IL-17A Alleviates Progression of Collagen-Induced Arthritis without Causing Serious Infections in Mice.
Fang Shen, Akash H Verma, Amy Volk, Brian Jones, Bianca M Coleman, Matthew J Loza

J Immunol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
I_MDS: an inflammatory bowel disease molecular activity score to classify patients with differing disease-driving pathways and therapeutic response to anti-TNF treatment.
Stelios Pavlidis, Calixte Monast, Matthew J Loza, Patrick Branigan, Kiang F Chung

PLoS Comput Biol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced oxidative stress in smoking and ex-smoking severe asthma in the U-BIOPRED cohort.
Rosalia Emma, Aruna T Bansal, Johan Kolmert, Craig E Wheelock, Swen-Erik Dahlen, Matthew J Loza

PLoS One· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epithelial IL-6 trans-signaling defines a new asthma phenotype with increased airway inflammation.
Zala Jevnikar, Jörgen Östling, Elisabeth Ax, Jenny Calvén, Kristofer Thörn, Matthew J Loza

J Allergy Clin Immunol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
"
"T2-high" in severe asthma related to blood eosinophil, exhaled nitric oxide and serum periostin.
Stelios Pavlidis, Kentaro Takahashi, Francois Ng Kee Kwong, Jiaxing Xie, Uruj Hoda, Matthew Loza

Eur Respir J· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2a study of toreforant, a histamine H receptor antagonist, in eosinophilic asthma.
Alexa P Kollmeier, Elliot S Barnathan, Christopher O'Brien, Bin Chen, Yichuan Karen Xia, Matthew J Loza

Ann Allergy Asthma Immunol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis